- Deep-tech startups in manufacturing, biotech and aerospace secured fresh funding across critical technology sectors
- Recent rounds backed precision printing, cell therapy, space chips and advanced medical devices
Dewu 3D raises pre-Series A round to scale micro-precision metal printing
Suzhou-based additive manufacturing company Dewu 3D (德悟科技) has raised hundreds of millions of yuan from a pre-Series A funding round, backed by GSR United Capital and Originvest.
The company will use the proceeds to further develop its high-precision selective laser melting (SLM) equipment, expand printing service capacity and accelerate market expansion.
Founded in May 2024, Dewu 3D focuses on micron-level metal additive manufacturing and is among a small group of Chinese companies developing core SLM technologies.
Its proprietary equipment achieves forming tolerances within ±10 microns and surface roughness as low as 1 micron. The technology can reduce post-processing costs from 70% of traditional solutions to 10%-20%, while lowering overall production costs by 30%-40%.
The company has established partnerships with listed suppliers in the consumer electronics supply chain, commercial aerospace research institutions and leading medical device manufacturers, and plans to expand into Japan, South Korea and Europe.
Renerval Therapeutics closes $22 million pre-Series A to advance iPSC therapies
Shanghai-based iPSC cell therapy company Renerval Therapeutics (河络新图) has completed a pre-Series A funding round worth 150 million yuan ($22 million), led by Efung Capital and Minhang Financial Investment, with existing investor Shunwei Capital also participating.
The funding will support clinical research and commercialization of its core pipelines.
Founded in 2021, Renerval focuses on iPSC reprogramming, precision gene editing, directed differentiation and organoid engineering.
Its key programs include universal artificial regenerative platelets and artificial red blood cells. The company’s artificial regenerative platelet program has entered human clinical trials.
AstraMatrix completes two funding rounds totaling nearly $15 million
Hangzhou-based aerospace chip developer AstraMatrix (星辰基石) has received around 100 million yuan across its angel and angel+ funding rounds.
The angel round was backed solely by Yinxinggu Capital, while the angel+ round was jointly invested by ZJU Youchance Capital, CETC Fund and Shanghai Angel Group.
The company will use the funding to scale production of its SDPC chip series and develop next-generation products.
Founded in September 2025 by experts from Zhejiang University’s aerospace and integrated circuit fields, AstraMatrix focuses on “system-chip co-design” and develops products around two areas: space-based digital energy and space-grade reliable computing.
Its technologies have already been integrated into supply chains of major aerospace organizations, including China Aerospace Science and Technology Corporation, China Electronics Technology Group Corporation and commercial space companies.
Its proprietary algorithms have been validated in orbit on satellites including SJ-21 and the Qianfan constellation.
Mingche Biotechnology raises Series A+ round for minimally invasive eye treatments
Suzhou-based ophthalmic medical device company Mingche Biotechnology (明澈生物) has bagged tens of millions of yuan in a Series A+ funding round led by Yuanbio Venture Capital.
The financing comes just six months after the company’s previous Series A round.
The funds will support domestic and overseas regulatory approval for its minimally invasive glaucoma surgery (MIGS) drainage device, as well as the development and clinical commercialization of its implantable collamer lens (ICL) technology.
Founded in 2021, Mingche’s R&D team includes academic experts, high-level medical specialists and ophthalmologists from leading hospitals.
The company has built a product pipeline covering minimally invasive treatments across both anterior and posterior segments of the eye.
